EVOLVE平台,一个具有集成CD2共刺激的三种特异性T细胞参与剂,用于固体和血液瘤的治疗
Oksana A Sergeeva1, Guixian Jin1, Mohosin Sarkar1
1EvolveImmune Therapeutics, Inc., Branford, CT 06405.
概括
将CD2代刺激集成到T细胞参与剂 (TCE) 中,可以提高T细胞活力和效应器功能. 这种新的EVOLVE平台改善了癌症免疫治疗的瘤杀伤和响应耐久性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 目前的T细胞参与者 (TCE) 由于缺乏辅助刺激信号,因此在持续的T细胞活动中面临限制.
- CD2受体为增强T细胞共刺激提供了一个有前途的标,因为它在T细胞受体信号和表达模式中的作用.
研究的目的:
- 研究将CD2辅助刺激整合到TCE中以改善T细胞效应器功能和抗瘤反应的有效性.
- 开发和评估一个下一代的TCE平台,称为EVOLVE,具有优化的CD3亲和和和CD2成本刺激.
主要方法:
- 在体外慢性刺激测试中,将CD2共刺激与其他途径进行比较.
- 使用CD58连接体进行CD2参与的抗体融合的开发.
- 在瘤模型 (HER2,CD20,B7-H4,ULBP2) 中,对具有集成CD2共刺激和不同CD3亲和度的TCE进行评估.
- 在小鼠模型中进行的体内疗效研究使用了针对ULBP2的三种特异物.
主要成果:
- 与其他途径相比,CD2辅助刺激在体外证明了T细胞活力和效应器功能的优越维护.
- 综合的CD2共刺激与减弱的CD3结合改善了治疗指数,并避免了目标独立的T细胞激活.
- 与CD3亲和相匹配的双特异物相比,EVOLVE平台对多种癌症点的瘤杀伤效果得到了增强.
- 在体内,具有CD2共刺激的ULBP2向的三种特异性药物表现优于更高亲和度的CD3分子.
结论:
- 集成CD2代刺激和优化CD3亲和度的EVOLVE平台,代表了TCE技术的重大进步.
- 这种方法在瘤微环境中增强T细胞效应器功能,可能提高抗瘤反应的深度和耐久性.
- 在癌症免疫疗法方面,EVOLVE平台有望解决未满足的患者需求.
更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.2K
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
17.7K
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
T Cell Activation and Clonal Selection
14.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.5K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Multipotency of Hematopoietic Stem Cells
3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
